Stock Traders Purchase High Volume of Call Options on Cooper Companies (NASDAQ:COO)

The Cooper Companies, Inc. (NASDAQ:COO) was the target of some unusual options trading on Tuesday. Stock investors acquired 4,056 call options on the company. This represents an increase of 411% compared to the average daily volume of 794 call options.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Traders purchased 4,056 call options on COO, roughly 411% above the typical daily volume of 794 contracts. This points to increased speculative bullish interest, although options activity alone does not guarantee a sustained stock advance.
• Neutral Sentiment: The latest short-interest report lists zero shares sold short and a 0.0-day short-interest ratio, but it also describes the change as “NaN” from a prior total of zero. The figures appear inconsistent and provide little useful information about investor positioning. Short Interest Report
• Negative Sentiment: COO’s valuation remains demanding, with a reported P/E ratio near 62. That can make the shares more sensitive to profit-taking or a lack of fresh positive catalysts, even though the company recently exceeded quarterly earnings and revenue expectations and reported year-over-year revenue growth.

Cooper Companies Trading Down 3.6%

NASDAQ:COO opened at $73.04 on Wednesday. Cooper Companies has a 12-month low of $58.89 and a 12-month high of $89.83. The firm has a market capitalization of $14.24 billion, a P/E ratio of 61.90, a P/E/G ratio of 1.98 and a beta of 0.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The business has a 50 day simple moving average of $72.20 and a 200 day simple moving average of $71.01.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm’s revenue was up 7.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Equities research analysts predict that Cooper Companies will post 4.63 EPS for the current year.

Institutional Trading of Cooper Companies

Several hedge funds have recently bought and sold shares of COO. Avalon Trust Co acquired a new stake in shares of Cooper Companies in the second quarter valued at approximately $25,000. Root Financial Partners LLC grew its holdings in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. grew its holdings in Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after buying an additional 187 shares in the last quarter. Elevation Wealth Partners LLC increased its position in Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 375 shares during the period. Finally, Continuum Advisory LLC acquired a new stake in Cooper Companies in the 2nd quarter valued at approximately $30,000. 24.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Citigroup restated a “neutral” rating and set a $80.00 price objective (up from $76.00) on shares of Cooper Companies in a research note on Thursday, August 13th. Robert W. Baird dropped their target price on shares of Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. JPMorgan Chase & Co. reduced their price target on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research report on Friday, June 5th. The Goldman Sachs Group set a $61.00 price target on shares of Cooper Companies in a report on Wednesday, May 27th. Finally, Weiss Ratings downgraded shares of Cooper Companies from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $81.64.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.